Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Amgen Inc. (AMGN : NSDQ)
 
 • Company Description   
Amgen Inc. is the leading biotech companies world wide, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health & nephrology and neuroscience markets. It developed two most successful drugs, Epogen & Neupogen. Amgen successfully launched two next-generation products, Aranesp & Neulasta and also a biosimilar drug, Prolia/Xgeva. The acquisition of Immunex Corp gave Amgen access to the multi-blockbuster drug, Enbrel. Other products are Repatha, Blincyto, Parsabiv, Evenity, Aimovig, Lumakras/Lumykras, Kanjinti, Mvasi & Amgevita biosimilars. Amgen also has a promising pipeline of cancer drugs. It has one of the strongest cash positions in the biotech sector, which could be used to acquire more pipeline assets that could fuel long-term growth. The erythropoiesis-stimulating agents and granulocyte colony-stimulating factor franchise comprise Epogen/Aranesp and Neupogen/Neulasta respectively. Biosimilar drugs are also a key part of Amgen's growth strategy.

Number of Employees: 24,200

 
 • Price / Volume Information   
Yesterday's Closing Price: $247.50 Daily Weekly Monthly
20 Day Moving Average: 3,456,034 shares
Shares Outstanding: 534.20 (millions)
Market Capitalization: $132,214.48 (millions)
Beta: 0.58
52 Week High: $258.45
52 Week Low: $198.64
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -1.14% 8.25%
12 Week 9.02% 22.52%
Year To Date 10.02% 34.40%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
ONE AMGEN CENTER DRIVE
-
THOUSAND OAKS,CA 91320
USA		 ph: 805-447-1000
fax: 805-447-1010		 investor.relations@amgen.com http://www.amgen.com
 
 • General Corporate Information   
Officers
Robert A. Bradway - Chief Executive Officer; Chairman of the Board; Pr
Peter H. Griffith - Executive Vice President and Chief Financial Offic
Linda H. Louie - Vice President; Finance and Chief Accounting Offic
Wanda M. Austin - Director
Brian J. Druker - Director

Peer Information
Amgen Inc. (CORR.)
Amgen Inc. (RSPI)
Amgen Inc. (CGXP)
Amgen Inc. (BGEN)
Amgen Inc. (GTBP)
Amgen Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 031162100
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/02/22
Share - Related Items
Shares Outstanding: 534.20
Most Recent Split Date: 11.00 (2.00:1)
Beta: 0.58
Market Capitalization: $132,214.48 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 3.14%
Current Fiscal Quarter EPS Consensus Estimate: $4.30 Indicated Annual Dividend: $7.76
Current Fiscal Year EPS Consensus Estimate: $17.48 Payout Ratio: 0.44
Number of Estimates in the Fiscal Year Consensus: 11.00 Change In Payout Ratio: 0.04
Estmated Long-Term EPS Growth Rate: 8.21% Last Dividend Paid: 05/16/2022 - $1.94
Next EPS Report Date: 08/02/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 14.16
Trailing 12 Months: 14.02
PEG Ratio: 1.72
Price Ratios
Price/Book: 144.34
Price/Cash Flow: 10.47
Price / Sales: 5.02
EPS Growth
vs. Year Ago Period: 14.86%
vs. Previous Quarter: -2.52%
Sales Growth
vs. Year Ago Period: 5.71%
vs. Previous Quarter: -8.88%
ROE
03/31/22 - 165.95
12/31/21 - 120.59
09/30/21 - 108.67
ROA
03/31/22 - 16.30
12/31/21 - 15.77
09/30/21 - 15.29
Current Ratio
03/31/22 - 1.44
12/31/21 - 1.59
09/30/21 - 1.64
Quick Ratio
03/31/22 - 1.09
12/31/21 - 1.26
09/30/21 - 1.36
Operating Margin
03/31/22 - 37.96
12/31/21 - 37.71
09/30/21 - 37.12
Net Margin
03/31/22 - 21.75
12/31/21 - 22.68
09/30/21 - 21.77
Pre-Tax Margin
03/31/22 - 24.77
12/31/21 - 25.79
09/30/21 - 25.02
Book Value
03/31/22 - 1.71
12/31/21 - 12.00
09/30/21 - 14.59
Inventory Turnover
03/31/22 - 1.56
12/31/21 - 1.58
09/30/21 - 1.57
Debt-to-Equity
03/31/22 - 39.31
12/31/21 - 4.96
09/30/21 - 4.05
Debt-to-Capital
03/31/22 - 97.52
12/31/21 - 83.22
09/30/21 - 80.20
 

Powered by Zacks Investment Research ©